These findings are of high clinical relevance because small-molecule inhibitors of PRMT5 are in pre-clinical development, exhibiting good in vivo efficacy against lymphomas and leukemia (Chan-Penebre et al., 2015, Jin et al., 2016). This evidence concerns the gene PRMT5 and lymphoma.